Dr. Reddy's Laboratories (NYS: RDY) reported earnings on Feb. 3. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q3), Dr. Reddy's Laboratories beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share increased significantly.
Margins increased across the board.
Dr. Reddy's Laboratories reported revenue of $521.9 million. The five analysts polled by S&P Capital IQ predicted sales of $496.2 million. Sales were 23% higher than the prior-year quarter's $425.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $0.56. The one earnings estimate compiled by S&P Capital IQ averaged $0.50 per share on the same basis. GAAP EPS of $0.57 for Q3 were 58% higher than the prior-year quarter's $0.36 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 59.9%, 500 basis points better than the prior-year quarter. Operating margin was 27.3%, 1,140 basis points better than the prior-year quarter. Net margin was 18.5%, 410 basis points better than the prior-year quarter.
On the bottom line, the average EPS estimate is $0.61.
Next year's average estimate for revenue is $1.86 billion. The average EPS estimate is $1.72.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 514 members out of 541 rating the stock outperform, and 27 members rating it underperform. Among 146 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 142 give Dr. Reddy's Laboratories a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Dr. Reddy's Laboratories is outperform, with an average price target of $34.48.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Dr. Reddy's Laboratories the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
Add Dr. Reddy's Laboratories to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Motley Fool newsletter services have recommended buying shares of Dr. Reddy's Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.